Strategies for initial management of hypertension

Indian Journal of Medical Research

Volumn 132, Issue 11, 2010, Pages 531-542

  Gupta, Rajeev ^a   Guptha, Soneil ^b  

^a FORTIS HOSPITAL   (India)

^b Regional Headquaters   (Singapore)

Author keywords

B blockers; Dietary therapy; High blood pressure; Lifestyle; Pharmacotherapy; Physical activity; Salt

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIET SUPPLEMENTATION; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INDIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORTALITY; POLYPHARMACY; PRACTICE GUIDELINE; PUBLIC HEALTH PROBLEM; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SMOKING CESSATION; SODIUM RESTRICTION; STRESS MANAGEMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; VEGETARIAN DIET; WEIGHT REDUCTION; ALCOHOLIC BEVERAGE; DIET THERAPY; DIETARY FIBER; DISEASE MANAGEMENT; POTASSIUM INTAKE; RISK REDUCTION; SALT INTAKE; SMOKING;

ALCOHOLIC BEVERAGES; ANTIHYPERTENSIVE AGENTS; DIET, VEGETARIAN; DIETARY FIBER; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; INDIA; POTASSIUM, DIETARY; RISK REDUCTION BEHAVIOR; SMOKING; SODIUM CHLORIDE, DIETARY;

EID: 78649482637     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
2. Gupta R, Al-Odat NA, Gupta VP. Hypertension epidemiology in India: meta-analysis of 50 year prevalence rates and blood pressure trends. J Hum Hypertens 1996; 10: 465-72.
3. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18: 73-8.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-504.
5. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J rd. Factors of risk in the development of coronary heart disease- six year follow-up experience. The Framingham Study. Ann Intern Med 1961; 55: 33-50.
6. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615.
7. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannell WB, et al. Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-7.
8. Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood pressure related cardiovascular disease. J Hypertens 2000; 18 (Suppl 1): S3-S6.
9. Gaziano T, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular disease. In: Jamison DT, Breman JG, Measham AR, Alleyene G, Cleason M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing world. Oxford: Oxford University Press; 2006. p. 645-62.
10. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
11. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9.
12. Kaplan NM. Treatment of hypertension: remaining issues after the Anglo-Scandinavian Cardiac Outcomes Trial. Hypertension 2006; 47: 10-3.
13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42: 1206-52.
14. Harrap SB. Where are all the blood pressure genes? Lancet 2003; 361: 2149-51.
15. Gupta R. Defining hypertension in the Indian population. Natl Med J India 1997; 10: 139-43.
16. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24.
17. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elper PT, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289: 2083-93.
18. [No authors listed]. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657-67.
19. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith-West D, et al, Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11.
20. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE): TONE collaborative research group. JAMA 1998; 279: 839-46.
21. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47: 296-308.
22. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.
23. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens 2001; 19: 1053-60.
24. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 1989; 2: 1244-7.
25. [No authors listed]. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ 1988; 297: 319-28.
26. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986; 8: II-127-34.
27. Dash SC, Sundaram KR, Swain PK. Blood pressure profile, urinary sodium and body weight in the 'Oraon' rural and urban tribal community. J Assoc Physicians India 1994; 42: 878-80.
28. Indian Council of Medical Research. Dietary guidelines for Indians- a manual. Hyderabad: National Institute of Nutrition, Indian Council of Medical Research; 2003.
29. Misra A, Khurana L. Salt intake and hypertension: walking the tight rope. J Assoc Physicians India 2007; 55: 401-3.
30. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624-32.
31. Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan S. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. BMJ 1990; 301: 521-3.
32. Klatsky AL, Friedman GD, Siegelaub AB, Gerard MJ. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med 1977; 296: 1194-200.
33. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001; 38: 1112-7.
34. He J, Whelton PK. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. Clin Exp Hypertens 1999; 21: 785-96.
35. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, et al; for the DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001; 135: 1019-28.
36. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, et al, OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005; 294: 2455-64.
37. Sacks FM, Kass EH. Low blood pressure in vegetarians: effects of specific foods and nutrients. Am J Clin Nutr 1988; 48 (Suppl 3): 795-800.
38. Achaya KT. Indian food: a historical companion. New Delhi. Oxford University Press; 1994.
39. Chadha SL, Gopinath N, KatyaI I, Shekhawat S. Dietary profile of adults in an urban & a rural community. Indian J Med Res 1995; 101: 258-67.
40. Chhajer B. Zero oil cook book. New Delhi: Fusion Books; 2008.
41. Ornish D. Dr Dean Ornish's program for reversing heart disease. New York: Random House; 1990.
42. Sindhwani V. Role of dietary modification with zero-oil diet in coronary artery disease patients. MSc dissertation. Delhi: Delhi University; 2004.
43. Reddy KS, Katan MB. Diet, nutrition and the prevention of hypertension and cardiovascular diseases. Public Health Nutr 2004; 7: 167-86.
44. Kim S, Popkin BM. Understanding the epidemiology of overweight and obesity: a real global public health concern. Int J Epidemiol 2006; 35: 60-7; discussion 81-2.
45. Gupta R, Deedwania PC. Obesity and the metabolic syndrome: management issues. In: Mohan V, Rao GHR. editors. Type 2 diabetes in South Asians: Epidemiology, risk factors and prevention. New Delhi: Jaypee Brothers Medical Publishers; 2006. p. 104-37.
46. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94: 16-26.
47. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-84.
48. Gupta R, Rastogi P, Sarna M, Gupta VP, Sharma SK, Kothari K. Body-mass index, waist-size, waist-hip ratio and cardiovascular risk factors in urban subjects. J Assoc Physicians India 2007; 55: 621-7.
49. Beilin LJ. The value of lifestyle in the management of hypertension. In: Kaplan NM. editor. Hypertension therapy annual. Martin Dunitz; 2000. p. 25-41.
50. Gupta R, Gupta VP, Singh V. Smoking and hypertension: the Indian scenario. South Asian J Prev Cardiol 2003; 7: 72-4.
51. Gupta R, Agarwal VS, Gupta VP, Soangra MR. Correlation of smoking, blood pressure levels and hypertension prevalence in urban and rural subjects. J Assoc Physicians India 1997; 45: 919-22.
52. Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007; 297: 286-94.
53. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized controlled trials. Ann Intern Med 2002; 136: 493-503.
54. Fagard RH, Cornelissen VA. Effect of exercise on blood pressure control in hypertensive patients. Eur J Cardiovasc Prev Rehabil 2007; 14: 12-7.
55. Udupa KN. Stress and its management by yoga. 2nd ed. Delhi: Motilal Banarsidass Publishers; 1985.
56. Patel C, Marmot MG, Terry DJ, Carruthers M, Hunt B, Patel M. Trial of relaxation in reducing coronary risk: four year follow up. Br Med J (Clin Res Ed) 1985; 290: 1103-6.
57. Van Montfrans GA, Karemaker JM, Wieling W, Dunning AJ. Relaxation therapy and continuous ambulatory blood pressure in mild hypertension: a controlled study. BMJ 1990; 300: 1368-72.
58. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24: 213-33.
59. European Society of Hypertension - European Society of Cardiology. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
60. Hermida RC, Ayala DE, Fernandez JR, Mojon A, Alonso I, Calvo C. Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol Int 2002; 19: 461-81.
61. Kario K, Pickering T G, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives; a prospective study. Circulation 2003; 107: 1401-6.
62. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
63. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988; 2: 397.
64. Taylor R. Conundrum of the HOPE Study: time of taking ramipril may account for lack of relation between blood pressure and outcome. BMJ 2003; 327: 681-2.
65. Wiliams B. The year in hypertension. J Am Coll Cardiol 2006; 48: 1698-711.
66. National Institute of Clinical Excellence. Hypertension: management of hypertension in adults in primary care. Available at: www. nice. org. uk/CG034, accessed on October 12, 2010.
67. Moser M, Pickering T, Sowers JR. Combination drug therapy in the management of hypertension: when, with what, and how? J Clin Hypertens 2000; 2: 94-8.
68. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
69. Treatment of hypertension in adults with diabetes. American Diabetes Association. Diabetes Care 2003; 26 (Suppl 1): S80-9.
70. National Kidney Foundation (NKF) Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kid Dis 2002; 39 (Suppl 2): S1-11.
71. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
72. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
73. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
74. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
75. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
76. Williams B. Treating hypertension: It is not how you start but where you end that matters. J Hypertens 2003; 21: 211-3.
77. Sharma AK, Gupta R, Sarna M, Gupta N, Gupta VP. Hypertension, pre-hypertension and cardiovascular risk factors in urban subjects. South Asian J Prev Cardiol 2009; 13: 82-70.
78. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-93.
79. Hansson L, Zanchetti A, Caruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
80. Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419-23.
81. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-10.
82. Rodgers RA, Lawes CMM, Gaziano T, Vos T. The growing burden of risk from high blood pressure, cholesterol and body weight. In: Jamison DT, Bremen JG, Measham AR, Alleyene G, Cleason M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing world. Oxford: Oxford University Press; 2006. p. 851-68.
83. Kaplan NM, Opie LH. Controversies in hypertension. Lancet 2006; 367: 168-76.